Bristol-Myers Squibb Co. (BMY)

54.27
0.63 1.20
NYSE : Health Technology
Prev Close 53.64
Open 53.60
Day Low/High 53.56 / 54.30
52 Wk Low/High 49.96 / 70.05
Volume 5.96M
Avg Volume 8.65M
Exchange NYSE
Shares Outstanding 1.63B
Market Cap 87.69B
EPS 0.60
P/E Ratio 92.50
Div & Yield 1.60 (2.88%)

Latest News

Tesla, Boeing and Merck Among Companies Hurt by Latest Tariffs

Tesla, Boeing and Merck Among Companies Hurt by Latest Tariffs

The latest announcement from the U.S. Trade Representative's office is chilling reading for free trade supporters.

China National Drug Administration Approves Country's First Immuno-Oncology Agent, Opdivo (nivolumab Injection), For Previously Treated Non-Small Cell Lung Cancer (NSCLC)

China National Drug Administration Approves Country's First Immuno-Oncology Agent, Opdivo (nivolumab Injection), For Previously Treated Non-Small Cell Lung Cancer (NSCLC)

Bristol-Myers Squibb Company (NYSE: BMY) announced today that the China National Drug Administration (CNDA) has approved Opdivo (nivolumab injection) for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior...

Bristol-Myers Squibb Announces Dividend

Bristol-Myers Squibb Announces Dividend

The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of forty cents ($0.

Bristol-Myers Squibb To Present New Research Findings On The Treatment Of Patients With Early Rheumatoid Arthritis At The Annual European Congress Of Rheumatology (EULAR 2018)

Bristol-Myers Squibb To Present New Research Findings On The Treatment Of Patients With Early Rheumatoid Arthritis At The Annual European Congress Of Rheumatology (EULAR 2018)

Bristol-Myers Squibb Company (NYSE: BMY) today confirmed that 31 abstracts demonstrating The Company's immunoscience-research focus as well as how ORENCIA ® (abatacept) therapy may impact diverse patient subgroups will be presented at the Annual European...

Bristol-Myers Squibb To Take Part In Goldman Sachs 39th Annual Global Healthcare Conference

Bristol-Myers Squibb To Take Part In Goldman Sachs 39th Annual Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE: BMY) will take part in Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13, 2018, in Rancho Palos Verdes, CA.

Bristol-Myers Squibb To Announce Results For Second Quarter 2018 On July 26

Bristol-Myers Squibb To Announce Results For Second Quarter 2018 On July 26

Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the second quarter of 2018 on Thursday, July 26, 2018.

ASCO's Big Winner: Loxo Oncology

ASCO's Big Winner: Loxo Oncology

Every year there are 'winners' and 'losers' from the biggest confab around oncology of the year.

Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug

Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug

Nektar Therapeutics shares got destroyed on Monday. Here is why.

Opdivo (nivolumab) 3 Mg/kg Demonstrates Sustained, Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) 10 Mg/kg For Broad Range Of Patients With Resected Stage III Or IV Melanoma

Opdivo (nivolumab) 3 Mg/kg Demonstrates Sustained, Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) 10 Mg/kg For Broad Range Of Patients With Resected Stage III Or IV Melanoma

Bristol-Myers Squibb Company (NYSE:BMY) today announced updated results from the Phase 3 CheckMate -238 trial evaluating Opdivo (nivolumab) versus Yervoy (ipilimumab) in patients with stage IIIB/C or stage IV melanoma who are at high risk of recurrence...

Preliminary Data For NKTR-214 In Combination With Opdivo (nivolumab) For Patients With Stage IV Metastatic Melanoma, Renal Cell Carcinoma, And Urothelial Cancers Presented At ASCO 2018

Preliminary Data For NKTR-214 In Combination With Opdivo (nivolumab) For Patients With Stage IV Metastatic Melanoma, Renal Cell Carcinoma, And Urothelial Cancers Presented At ASCO 2018

Data from the Phase 1 dose-escalation and early data from the Phase 2 dose expansion phase of the ongoing PIVOT study highlighted as an oral presentation

U.S. Food And Drug Administration Lifts Partial Clinical Hold On Opdivo (nivolumab)-based Combination Study In Multiple Myeloma

U.S. Food And Drug Administration Lifts Partial Clinical Hold On Opdivo (nivolumab)-based Combination Study In Multiple Myeloma

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S.

Opdivo (nivolumab) Plus Low-Dose (1mg/kg) Yervoy (ipilimumab) Provided Significant And Sustained Health-Related Quality Of Life Improvements In Intermediate- And Poor-Risk Patients With Advanced Renal Cell Carcinoma In CheckMate -214 Study

Opdivo (nivolumab) Plus Low-Dose (1mg/kg) Yervoy (ipilimumab) Provided Significant And Sustained Health-Related Quality Of Life Improvements In Intermediate- And Poor-Risk Patients With Advanced Renal Cell Carcinoma In CheckMate -214 Study

Bristol-Myers Squibb Company (NYSE:BMY) today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC) treated with the Immuno-Oncology combination...

Bristol-Myers Squibb To Hold Investor Event To Discuss ASCO Highlights

Bristol-Myers Squibb To Hold Investor Event To Discuss ASCO Highlights

Bristol-Myers Squibb Company (NYSE:BMY) will hold an investor event on Monday, June 4, 2018 at 8:30 p.

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

President Trump's appetite for TV and ratings is legendary and now the administration wants to require drug company TV ads to include the list price of prescription drugs.

When the Stock Is the Only Option

When the Stock Is the Only Option

Options spreads aren't tradable with some small biotechs, making shares the only way to play.

Bristol-Myers Squibb Highlights Breadth Of Immuno-Oncology-Based Combination Research And Commitment To Advancing Precision Medicine At ASCO 2018

Bristol-Myers Squibb Highlights Breadth Of Immuno-Oncology-Based Combination Research And Commitment To Advancing Precision Medicine At ASCO 2018

Bristol-Myers Squibb Company (NYSE:BMY) today announced that data from over 70 Company-sponsored studies and collaborations evaluating its oncology compounds across more than 20 types of cancer will be featured at the American Society of Clinical Oncology...

Consolidated Edison, Chesapeake Energy: 'Mad Money' Lightning Round

Consolidated Edison, Chesapeake Energy: 'Mad Money' Lightning Round

Jim Cramer weighs in on Consolidated Edison, Clorox, Chesapeake Energy, Adaptimmune Therapeutics, Icahn Enterprises, Bristol-Meyers Squibb and more.

Where the Bears Are: Cramer's 'Mad Money' Recap (Tuesday 5/15/18)

Where the Bears Are: Cramer's 'Mad Money' Recap (Tuesday 5/15/18)

Get ahead of the naysayers, says Jim Cramer. FANG and other tech leaders have gone cold, but they're not dead yet.

Bristol-Myers Squibb To Take Part In UBS 2018 Global Healthcare Conference

Bristol-Myers Squibb To Take Part In UBS 2018 Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the UBS 2018 Global Healthcare Conference on Tuesday, May 22, 2018, in New York.

Being Bullish on Trump Surprisingly Worked Well for Investors This Week

Being Bullish on Trump Surprisingly Worked Well for Investors This Week

President Trump reduced tensions in Korea, raised them in the Middle East, and mainly relieved them for investors in the drug and healthcare industries.

Surveying the M&A Landscape in Biotech

Surveying the M&A Landscape in Biotech

Who might be in play in the quarters ahead?

European Medicines Agency Validates Bristol-Myers Squibb's Type II Variation Application For Opdivo Plus Yervoy Combination For Treatment Of First-Line Metastatic Non-Small Cell Lung Cancer (NSCLC)

European Medicines Agency Validates Bristol-Myers Squibb's Type II Variation Application For Opdivo Plus Yervoy Combination For Treatment Of First-Line Metastatic Non-Small Cell Lung Cancer (NSCLC)

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Medicines Agency (EMA) validated a type II variation application for the Opdivo (nivolumab) plus Yervoy (ipilimumab) combination for treatment in adult patients with first-line...

Bristol-Myers Squibb And Flatiron Health Expand Collaboration With A Three-Year Agreement

Bristol-Myers Squibb And Flatiron Health Expand Collaboration With A Three-Year Agreement

Bristol-Myers Squibb (NYSE:BMY) and Flatiron Health, a market leader in oncology-specific electronic health record software and the curation of regulatory-grade real-world data for cancer research and real-world evidence (RWE) generation, expanded their...

4 Keys to Staying Alive in Tough Markets -- And How I'm Playing 3 Big Tech Names

4 Keys to Staying Alive in Tough Markets -- And How I'm Playing 3 Big Tech Names

KLA-Tencor, Microsoft and Intel all report earnings after the close Thursday.

Facebook, Amazon, Microsoft and Ford - 5 Things You Must Know

Facebook, Amazon, Microsoft and Ford - 5 Things You Must Know

U.S. stock futures suggest Wall Street will open with modest gains on Thursday; Facebook posts a blowout quarter; Amazon and Microsoft to report earnings; Ford is no longer a car company.

Global Stocks Mixed, U.S. Futures Soften as Earnings, Oil, Rates Cloud Sentiment

Global Stocks Mixed, U.S. Futures Soften as Earnings, Oil, Rates Cloud Sentiment

Rising oil prices, surging bond yields and mixed earnings forecasts have stalled overnight gains for global stocks and pulled U.S. equity futures into the red ahead of another hectic slate of corporate reports.

Bristol-Myers Squibb Reports First Quarter Financial Results

Bristol-Myers Squibb Reports First Quarter Financial Results

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2018 which were highlighted by strong sales for Opdivo , Eliquis , and Orencia, important regulatory progress in Immuno-Oncology and strategic business...

European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) Four-Week Dosing Schedule For Advanced Melanoma And Previously Treated Renal Cell Carcinoma

European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) Four-Week Dosing Schedule For Advanced Melanoma And Previously Treated Renal Cell Carcinoma

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has approved an every four-week (Q4W) Opdivo (nivolumab) monotherapy dosing schedule of 480 mg infused over 60 minutes as an option for patients with advanced...

TheStreet Quant Rating: C (Hold)